Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions
Transfusion of platelet concentrates remains the first-line therapy for Glanzmann thrombasthenia in case of bleeding or preparation for surgery. However, development of antibodies to platelet glycoprotein (Gp) IIb/IIIa complex or human leukocyte antigens (HLA) is frequent and the main cause o...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hacettepe University Institute of Child Health
2003-01-01
|
| Series: | The Turkish Journal of Pediatrics |
| Online Access: | https://turkjpediatr.org/article/view/2858 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850236816887644160 |
|---|---|
| author | Omer Devecioğlu Ayşegül Unüvar Sema Anak Ilmay Bilge Haluk Ander Orhan Ziylan |
| author_facet | Omer Devecioğlu Ayşegül Unüvar Sema Anak Ilmay Bilge Haluk Ander Orhan Ziylan |
| author_sort | Omer Devecioğlu |
| collection | DOAJ |
| description |
Transfusion of platelet concentrates remains the first-line therapy for Glanzmann thrombasthenia in case of bleeding or preparation for surgery. However, development of antibodies to platelet glycoprotein (Gp) IIb/IIIa complex or human leukocyte antigens (HLA) is frequent and the main cause of platelet refractoriness. Recombinant activated factor VII (rFVIIa) is a potent alternative for patients with Glanzmann thrombasthenia with anti-platelet antibodies. We describe a case of Glanzmann thrombasthenia with alloantibodies to platelet Gp IIb/IIIa complex who underwent a successful pyelolithotomy operation under the coverage of recombinant activated factor VIIa and platelet transfusions.
|
| format | Article |
| id | doaj-art-3e5cbb5edfb4471eb6e63ab4b1fc4429 |
| institution | OA Journals |
| issn | 0041-4301 2791-6421 |
| language | English |
| publishDate | 2003-01-01 |
| publisher | Hacettepe University Institute of Child Health |
| record_format | Article |
| series | The Turkish Journal of Pediatrics |
| spelling | doaj-art-3e5cbb5edfb4471eb6e63ab4b1fc44292025-08-20T02:01:54ZengHacettepe University Institute of Child HealthThe Turkish Journal of Pediatrics0041-43012791-64212003-01-01451Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusionsOmer Devecioğlu0Ayşegül UnüvarSema AnakIlmay BilgeHaluk AnderOrhan ZiylanDivision of Hematology/Oncology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey. Transfusion of platelet concentrates remains the first-line therapy for Glanzmann thrombasthenia in case of bleeding or preparation for surgery. However, development of antibodies to platelet glycoprotein (Gp) IIb/IIIa complex or human leukocyte antigens (HLA) is frequent and the main cause of platelet refractoriness. Recombinant activated factor VII (rFVIIa) is a potent alternative for patients with Glanzmann thrombasthenia with anti-platelet antibodies. We describe a case of Glanzmann thrombasthenia with alloantibodies to platelet Gp IIb/IIIa complex who underwent a successful pyelolithotomy operation under the coverage of recombinant activated factor VIIa and platelet transfusions. https://turkjpediatr.org/article/view/2858 |
| spellingShingle | Omer Devecioğlu Ayşegül Unüvar Sema Anak Ilmay Bilge Haluk Ander Orhan Ziylan Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions The Turkish Journal of Pediatrics |
| title | Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions |
| title_full | Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions |
| title_fullStr | Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions |
| title_full_unstemmed | Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions |
| title_short | Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions |
| title_sort | pyelolithotomy in a patient with glanzmann thrombasthenia and antiglycoprotein iib iiia antibodies the shortest possible duration of treatment with recombinant activated factor vii and platelet transfusions |
| url | https://turkjpediatr.org/article/view/2858 |
| work_keys_str_mv | AT omerdevecioglu pyelolithotomyinapatientwithglanzmannthrombastheniaandantiglycoproteiniibiiiaantibodiestheshortestpossibledurationoftreatmentwithrecombinantactivatedfactorviiandplatelettransfusions AT aysegulunuvar pyelolithotomyinapatientwithglanzmannthrombastheniaandantiglycoproteiniibiiiaantibodiestheshortestpossibledurationoftreatmentwithrecombinantactivatedfactorviiandplatelettransfusions AT semaanak pyelolithotomyinapatientwithglanzmannthrombastheniaandantiglycoproteiniibiiiaantibodiestheshortestpossibledurationoftreatmentwithrecombinantactivatedfactorviiandplatelettransfusions AT ilmaybilge pyelolithotomyinapatientwithglanzmannthrombastheniaandantiglycoproteiniibiiiaantibodiestheshortestpossibledurationoftreatmentwithrecombinantactivatedfactorviiandplatelettransfusions AT halukander pyelolithotomyinapatientwithglanzmannthrombastheniaandantiglycoproteiniibiiiaantibodiestheshortestpossibledurationoftreatmentwithrecombinantactivatedfactorviiandplatelettransfusions AT orhanziylan pyelolithotomyinapatientwithglanzmannthrombastheniaandantiglycoproteiniibiiiaantibodiestheshortestpossibledurationoftreatmentwithrecombinantactivatedfactorviiandplatelettransfusions |